Your browser doesn't support javascript.
loading
Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015).
Iijima, Hiroko; Kudo, Masatoshi; Kubo, Shoji; Kurosaki, Masayuki; Sakamoto, Michiie; Shiina, Shuichiro; Tateishi, Ryosuke; Osamu, Nakashima; Fukumoto, Takumi; Matsuyama, Yutaka; Murakami, Takamichi; Takahashi, Arata; Miyata, Hiroaki; Kokudo, Norihiro.
Afiliación
  • Iijima H; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Kudo M; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
  • Kubo S; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Kurosaki M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Sakamoto M; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Shiina S; Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Tateishi R; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Osamu N; Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Fukumoto T; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Matsuyama Y; School of Medicine, International University of Health and Welfare, Tokyo, Japan.
  • Murakami T; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Takahashi A; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.
  • Miyata H; Follow-up Survey Committee, Japan Liver Cancer Association, Osaka, Japan.
  • Kokudo N; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hepatol Res ; 53(10): 895-959, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37574758
ABSTRACT
For the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20 889 newly registered patients and 42 274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from January 1, 2014 to December 31, 2015. Basic statistics compiled for patients newly registered in the 23rd survey were cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. The median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child-Pugh grade, or albumin-bilirubin grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Hepatol Res Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Hepatol Res Año: 2023 Tipo del documento: Article País de afiliación: Japón